Authors

• Barbara Ink
• Akihiko Asahina (ORCID: https://orcid.org/0000-0001-6127-3182)
• Jason Coarse
• Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
• Rajan Bajracharya (ORCID: https://orcid.org/0009-0000-7857-8783)
• Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
• Alice Bendix Gottlieb (ORCID: https://orcid.org/0000-0002-2927-8618)
• Wolf‐­Henning Boehncke (ORCID: https://orcid.org/0000-0002-1225-7124)
• Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)
• Diamant Thaçi (ORCID: https://orcid.org/0000-0001-8513-550X)
• Heather Edens

Institutions

• University of Geneva (CH)
• Jikei University School of Medicine (JP)
• Manchester Academic Health Science Centre (GB)
• Southwestern Medical Center (US)
• University Hospital of Geneva (CH)
• NIHR Manchester Biomedical Research Centre (GB)
• Geneva College (US)
• The University of Texas Southwestern Medical Center (US)
• University of Lübeck (DE)
• Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal

Dermatology and Therapy

Published

2025-12-12

DOI

https://doi.org/10.1007/s13555-025-01599-5

Primary Topic

Spondyloarthritis Studies and Treatments

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Amgen
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• Sanofi
• Biogen
• Celgene
• University of Texas Southwestern Medical Center
• Regeneron Pharmaceuticals
• Incyte
• Celltrion
• Castle Biosciences
• Meiji Seika Pharma
• Astellas Pharma
• Galderma
• Sun Pharma
• LEO Pharma
• Genentech